Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Background In the international, phase III, randomized, double-blind CORRECT trial, regorafenib significantly prolonged overall survival (OS) versus placebo in patients with metastatic colorectal cancer (mCRC) that had progressed on all standard therapies. This post hoc analysis evaluated the effica...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Invest New Drugs
Hlavní autoři: Yoshino, Takayuki, Komatsu, Yoshito, Yamada, Yasuhide, Yamazaki, Kentaro, Tsuji, Akihito, Ura, Takashi, Grothey, Axel, Van Cutsem, Eric, Wagner, Andrea, Cihon, Frank, Hamada, Yoko, Ohtsu, Atsushi
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2014
Témata:
Phase III Studies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434855/
https://ncbi.nlm.nih.gov/pubmed/25213161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0154-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky